Velu umesh (10 risultati)

Condizione: New.

Condizione: New. In English.

Taschenbuch. Condizione: Neu. EGFR expression and the role of Gefitinib in Oral cavity lesions | Expression of EGFR in Premalignant and Malignant lesions of the oral cavity and evaluating the role of Gefitinib | Umesh Velu (u. a.) | Taschenbuch | 56 S. | Englisch | 2013 | LAP LAMBERT Academic Publishing | EAN 9783659373558 | Verantwortliche Person für die EU: OmniScriptum GmbH & Co. KG, Bahnhofstr. 28, 66111 Saarbrücken, info[at]akademikerverlag[dot]de | Anbieter: preigu.…

PF. Condizione: New. This item is printed on demand. Brand new book, sourced directly from publisher. Dispatch time is 6-7 days from our warehouse. Book will be sent in robust, secure packaging to ensure it reaches you securely.

PAP. Condizione: New. New Book. Shipped from UK. THIS BOOK IS PRINTED ON DEMAND. Established seller since 2000.

PAP. Condizione: New. New Book. Delivered from our UK warehouse in 4 to 14 business days. THIS BOOK IS PRINTED ON DEMAND. Established seller since 2000.

Taschenbuch. Condizione: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -Oral Cavity cancer is the 10th most common malignancy globally. EGFR is a glycoprotein encoded by a gene located on chromosome 7p12. Stimulation of EGFR will activate an intracellular signalling pathway, leading to the inhibition of apoptosis, activation of cell proliferation and angiogenesis, as well as an increase in metastatic spread potential. In premalignant lesions EGFR can be considered as an early marker of a cell proliferation on cell differentiation as well as early marker of epithelial dysplasia and onset of cancer in oral premaligant lesions. Hence cancers of oral cavity can be prevented and progress of carcinogenisis may be stopped at a early stage. EGFR evaluation can be used as a Screening tool in premalignant lesions to determine its malignant potential. In Malignant it has been seen that there is better response to treatment when EGFR Inhibitor Gefitinib was combined to the standard regimen of CCRT in Locally advanced Oral cavity malignant lesions. 56 pp. Englisch.…

Taschenbuch. Condizione: Neu. nach der Bestellung gedruckt Neuware - Printed after ordering - Oral Cavity cancer is the 10th most common malignancy globally. EGFR is a glycoprotein encoded by a gene located on chromosome 7p12. Stimulation of EGFR will activate an intracellular signalling pathway, leading to the inhibition of apoptosis, activation of cell proliferation and angiogenesis, as well as an increase in metastatic spread potential. In premalignant lesions EGFR can be considered as an early marker of a cell proliferation on cell differentiation as well as early marker of epithelial dysplasia and onset of cancer in oral premaligant lesions. Hence cancers of oral cavity can be prevented and progress of carcinogenisis may be stopped at a early stage. EGFR evaluation can be used as a Screening tool in premalignant lesions to determine its malignant potential. In Malignant it has been seen that there is better response to treatment when EGFR Inhibitor Gefitinib was combined to the standard regimen of CCRT in Locally advanced Oral cavity malignant lesions. …

Condizione: New. Dieser Artikel ist ein Print on Demand Artikel und wird nach Ihrer Bestellung fuer Sie gedruckt. Autor/Autorin: Velu UmeshDr Umesh V completed his MBBS from the prestigious Mysore Medical College and Research Institute, Mysore (2004 Batch). Currently he is pursuing his M D in Radiation Oncology at J K Cancer Institute GSVM Medical college Kan.…

Taschenbuch. Condizione: Neu. This item is printed on demand - Print on Demand Titel. Neuware -Oral Cavity cancer is the 10th most common malignancy globally. EGFR is a glycoprotein encoded by a gene located on chromosome 7p12. Stimulation of EGFR will activate an intracellular signalling pathway, leading to the inhibition of apoptosis, activation of cell proliferation and angiogenesis, as well as an increase in metastatic spread potential. In premalignant lesions EGFR can be considered as an early marker of a cell proliferation on cell differentiation as well as early marker of epithelial dysplasia and onset of cancer in oral premaligant lesions. Hence cancers of oral cavity can be prevented and progress of carcinogenisis may be stopped at a early stage. EGFR evaluation can be used as a Screening tool in premalignant lesions to determine its malignant potential. In Malignant it has been seen that there is better response to treatment when EGFR Inhibitor Gefitinib was combined to the standard regimen of CCRT in Locally advanced Oral cavity malignant lesions.VDM Verlag, Dudweiler Landstraße 99, 66123 Saarbrücken 56 pp. Englisch. …